Graves' disease laboratory findings: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Graves' disease}} | {{Graves' disease}} | ||
{{CMG}},{{AE}}{{MehdiP}} | |||
{{CMG}} | |||
==Overview== | ==Overview== | ||
The laboratory findings for Graves' disease are elevated levels of serum thyroxine (T4) and triiodothyronine (T3) and undetectable serum TSH. | |||
== Laboratory Findings == | == Laboratory Findings == | ||
The laboratory findings for Graves' disease are: | |||
*Elevated levels of serum thyroxine (T4) and triiodothyronine (T3) | |||
*Undetectable serum TSH. | |||
Total T4 and T3 measurements are influenced by multiple conditions affecting serum thyroxine-binding globulin (TBG) thus, free thyroid hormone (free T4 (FT4) and free T3 (fT3)) are the gold standard measurements to diagnose Graves' disease.<ref name="pmid17673120">{{cite journal |vauthors=Dufour DR |title=Laboratory tests of thyroid function: uses and limitations |journal=Endocrinol. Metab. Clin. North Am. |volume=36 |issue=3 |pages=579–94, v |year=2007 |pmid=17673120 |doi=10.1016/j.ecl.2007.04.003 |url=}}</ref><br> | |||
Antibodies against the TSH receptor (TRAbs) are pathognomonic for Graves' disease. They are detectable in the serum of about 98% of untreated patients.<ref name="pmid20594972">{{cite journal |vauthors=Zöphel K, Roggenbuck D, Schott M |title=Clinical review about TRAb assay's history |journal=Autoimmun Rev |volume=9 |issue=10 |pages=695–700 |year=2010 |pmid=20594972 |doi=10.1016/j.autrev.2010.05.021 |url=}}</ref> | |||
<br>Detection of TRAbs rules out other causes of thyrotoxicosis.<ref name="pmid23539719">{{cite journal |vauthors=Barbesino G, Tomer Y |title=Clinical review: Clinical utility of TSH receptor antibodies |journal=J. Clin. Endocrinol. Metab. |volume=98 |issue=6 |pages=2247–55 |year=2013 |pmid=23539719 |pmc=3667257 |doi=10.1210/jc.2012-4309 |url=}}</ref><br> | |||
Nnti-thyroid peroxidase (TPO) and antithyroglobulin (Tg) antibodies are also detectable in many patients with Graves' disease but it's not recommended to measure them in all patients for diagnosis. | |||
==References== | ==References== | ||
| Line 19: | Line 20: | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category:Endocrinology]] | ||
[[Category:Medicine]] | |||
[[Category:Primary care]] | |||
Revision as of 15:31, 20 December 2016
|
Graves' disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Graves' disease laboratory findings On the Web |
|
American Roentgen Ray Society Images of Graves' disease laboratory findings |
|
Risk calculators and risk factors for Graves' disease laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Overview
The laboratory findings for Graves' disease are elevated levels of serum thyroxine (T4) and triiodothyronine (T3) and undetectable serum TSH.
Laboratory Findings
The laboratory findings for Graves' disease are:
- Elevated levels of serum thyroxine (T4) and triiodothyronine (T3)
- Undetectable serum TSH.
Total T4 and T3 measurements are influenced by multiple conditions affecting serum thyroxine-binding globulin (TBG) thus, free thyroid hormone (free T4 (FT4) and free T3 (fT3)) are the gold standard measurements to diagnose Graves' disease.[1]
Antibodies against the TSH receptor (TRAbs) are pathognomonic for Graves' disease. They are detectable in the serum of about 98% of untreated patients.[2]
Detection of TRAbs rules out other causes of thyrotoxicosis.[3]
Nnti-thyroid peroxidase (TPO) and antithyroglobulin (Tg) antibodies are also detectable in many patients with Graves' disease but it's not recommended to measure them in all patients for diagnosis.
References
- ↑ Dufour DR (2007). "Laboratory tests of thyroid function: uses and limitations". Endocrinol. Metab. Clin. North Am. 36 (3): 579–94, v. doi:10.1016/j.ecl.2007.04.003. PMID 17673120.
- ↑ Zöphel K, Roggenbuck D, Schott M (2010). "Clinical review about TRAb assay's history". Autoimmun Rev. 9 (10): 695–700. doi:10.1016/j.autrev.2010.05.021. PMID 20594972.
- ↑ Barbesino G, Tomer Y (2013). "Clinical review: Clinical utility of TSH receptor antibodies". J. Clin. Endocrinol. Metab. 98 (6): 2247–55. doi:10.1210/jc.2012-4309. PMC 3667257. PMID 23539719.